Figure 1.
![Time to presentation with thrombocytopenia following the most recent dose of a SARS-CoV-2 vaccine. The graph compares vaccine type (Pfizer-BioNTech [n = 39] and Moderna [n = 37]) in persons without reported preexisting platelet disorders.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/139/10/10.1182_blood.2021013411/7/bloodbld2021013411f1.png?Expires=1735516399&Signature=p0VkjIclN~1jzSwa3CEvND9Wg3wqJZ4ThlTb6Uk2u8Rd-14Nh3w6RGHWaxA48pfCbXVuju0M97HJNWskwkNTA-~aS0ZUyIHiaA8OrNr8vaS6kfChQ1-qI2n9sfX~xBVWHrzZ~n1RE8t-AXH4ALb-RuoY1L2sQlrzWm0Yv1syRICzK3ntEbmSRQ3yL-Rh1FfIpRS25iaEUPp9wGfBoJGmFholFCngyunIE~0ubr3uEbzU03BqLAdw4N2Vkcogu8gYXNTafNdLyl8ov1dt3o8A46Y32-5HarDJOEnCqmKuTiW7ZNXCB2pgco0hs2DkPm2VXWJqseN021My-JggmCSAhQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Time to presentation with thrombocytopenia following the most recent dose of a SARS-CoV-2 vaccine. The graph compares vaccine type (Pfizer-BioNTech [n = 39] and Moderna [n = 37]) in persons without reported preexisting platelet disorders.
Time to presentation with thrombocytopenia following the most recent dose of a SARS-CoV-2 vaccine. The graph compares vaccine type (Pfizer-BioNTech [n = 39] and Moderna [n = 37]) in persons without reported preexisting platelet disorders.